Graduate School of Biomedical Engineering

A method to produce blood thinning drug - Heparin

OUR TECHNOLOGIES

A method to produce blood thinning drug, heparin via the recombinant expression of the protein core that is naturally decorated with the carbohydrate heparin and the culture of these cells in bioreactor conditions that promote the production of heparin chains with anticoagulant activity. PCT filed in April 2016. US patent filed in November 2016.



APPLICATIONS

- Anticoagulant blood thinning drug, heparin
- Method to produce other glycosylated therapeutic molecules
- Method to produce bioactive for biomaterials, tissue engineering and regenerative medicine

INDUSTRY OPPORTUNITIES

The technology is currently in an incubation phase at UNSW. The inventors are looking to translate this technology to industry through:

- Industrial partnerships
- Capital investment for a start-up venture.

OUR EXPERTS

A/Prof Megan Lord is a chemical engineer and expert in the production of engineered materials and bioengineered molecules for biomaterials applications. She has led successful industry partnership projects with Cochlear, HemCon Medical Technologies, Sydnegen Inc and the Australian Red Cross Blood Service.

Prof Whitelock is a biomedical scientist and world-renowned proteoglycan expert. He has a proven track record working with industry through being a member of the Scientific Advisory Board of Agenta Biotechnologies. He spent 5 years at CSIRO prior to joining UNSW. He has led successful industry partnership grants with Proteome Systems, HemCon Medical Technologies, Sydnegen Inc and the Australian Red Cross Blood Service.

新南威尔士大学火炬创新园区
Torch Innovation Precinct at UNSW

More information contact: A/Prof Megan Lord (m.lord@unsw.edu.au) T: +61 2 9385 3910; Prof Whitelock (j.whitelock@unsw.edu.au), T: +61 2 9385 3948